MX2007002879A - Combinacion de compuestos organicos. - Google Patents
Combinacion de compuestos organicos.Info
- Publication number
- MX2007002879A MX2007002879A MX2007002879A MX2007002879A MX2007002879A MX 2007002879 A MX2007002879 A MX 2007002879A MX 2007002879 A MX2007002879 A MX 2007002879A MX 2007002879 A MX2007002879 A MX 2007002879A MX 2007002879 A MX2007002879 A MX 2007002879A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- inhibitors
- pharmaceutically acceptable
- disease
- diseases
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 89
- 150000003839 salts Chemical class 0.000 claims abstract description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 239000000556 agonist Substances 0.000 claims abstract description 30
- 239000003112 inhibitor Substances 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 239000002461 renin inhibitor Substances 0.000 claims abstract description 17
- 229940086526 renin-inhibitors Drugs 0.000 claims abstract description 17
- 208000035475 disorder Diseases 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 230000009467 reduction Effects 0.000 claims abstract description 13
- 230000000391 smoking effect Effects 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 12
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims abstract description 11
- 229940126033 PPAR agonist Drugs 0.000 claims abstract description 11
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims abstract description 11
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 10
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 10
- 229940122388 Thrombin inhibitor Drugs 0.000 claims abstract description 10
- 230000003178 anti-diabetic effect Effects 0.000 claims abstract description 10
- 230000001906 cholesterol absorption Effects 0.000 claims abstract description 10
- 239000003868 thrombin inhibitor Substances 0.000 claims abstract description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 10
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims abstract description 9
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims abstract description 9
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims abstract description 9
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 claims abstract description 9
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 claims abstract description 9
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims abstract description 9
- 229940122904 Glucagon receptor antagonist Drugs 0.000 claims abstract description 9
- 102100040918 Pro-glucagon Human genes 0.000 claims abstract description 9
- 229960002478 aldosterone Drugs 0.000 claims abstract description 9
- 206010020772 Hypertension Diseases 0.000 claims abstract description 8
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 8
- 239000000883 anti-obesity agent Substances 0.000 claims abstract description 8
- 229940030600 antihypertensive agent Drugs 0.000 claims abstract description 8
- 239000002220 antihypertensive agent Substances 0.000 claims abstract description 8
- 229940125710 antiobesity agent Drugs 0.000 claims abstract description 8
- 239000003937 drug carrier Substances 0.000 claims abstract description 8
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 8
- 208000008589 Obesity Diseases 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 235000020824 obesity Nutrition 0.000 claims abstract description 7
- 206010019280 Heart failures Diseases 0.000 claims abstract description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 6
- 241000124008 Mammalia Species 0.000 claims abstract description 6
- 208000037803 restenosis Diseases 0.000 claims abstract description 6
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 5
- 208000006575 hypertriglyceridemia Diseases 0.000 claims abstract description 5
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 4
- FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 claims abstract description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 4
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 4
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 4
- 208000011231 Crohn disease Diseases 0.000 claims abstract description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims abstract description 4
- 206010014950 Eosinophilia Diseases 0.000 claims abstract description 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims abstract description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 4
- 206010061218 Inflammation Diseases 0.000 claims abstract description 4
- 206010022562 Intermittent claudication Diseases 0.000 claims abstract description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 4
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 4
- 206010063837 Reperfusion injury Diseases 0.000 claims abstract description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 4
- 201000004810 Vascular dementia Diseases 0.000 claims abstract description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 4
- 239000003472 antidiabetic agent Substances 0.000 claims abstract description 4
- 206010003246 arthritis Diseases 0.000 claims abstract description 4
- 208000006673 asthma Diseases 0.000 claims abstract description 4
- 210000000481 breast Anatomy 0.000 claims abstract description 4
- 201000011510 cancer Diseases 0.000 claims abstract description 4
- 230000000747 cardiac effect Effects 0.000 claims abstract description 4
- 230000005961 cardioprotection Effects 0.000 claims abstract description 4
- 210000001072 colon Anatomy 0.000 claims abstract description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 4
- 208000010643 digestive system disease Diseases 0.000 claims abstract description 4
- 230000006872 improvement Effects 0.000 claims abstract description 4
- 230000004054 inflammatory process Effects 0.000 claims abstract description 4
- 230000028709 inflammatory response Effects 0.000 claims abstract description 4
- 208000021156 intermittent vascular claudication Diseases 0.000 claims abstract description 4
- 230000002503 metabolic effect Effects 0.000 claims abstract description 4
- 230000004060 metabolic process Effects 0.000 claims abstract description 4
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 4
- 229960002715 nicotine Drugs 0.000 claims abstract description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 201000001474 proteinuria Diseases 0.000 claims abstract description 4
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 4
- 208000017520 skin disease Diseases 0.000 claims abstract description 4
- 208000019553 vascular disease Diseases 0.000 claims abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims abstract description 3
- 229940126904 hypoglycaemic agent Drugs 0.000 claims abstract description 3
- 201000006370 kidney failure Diseases 0.000 claims abstract description 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims abstract 4
- 206010027525 Microalbuminuria Diseases 0.000 claims abstract 3
- 230000002757 inflammatory effect Effects 0.000 claims abstract 3
- 208000028867 ischemia Diseases 0.000 claims abstract 3
- 206010012335 Dependence Diseases 0.000 claims abstract 2
- 229960003920 cocaine Drugs 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 10
- 239000005541 ACE inhibitor Substances 0.000 claims description 7
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 7
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 7
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 7
- 239000002876 beta blocker Substances 0.000 claims description 7
- 229940097320 beta blocking agent Drugs 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 230000009977 dual effect Effects 0.000 claims description 4
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 230000009610 hypersensitivity Effects 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 3
- 229940044551 receptor antagonist Drugs 0.000 claims description 3
- 230000035939 shock Effects 0.000 claims description 3
- 201000005665 thrombophilia Diseases 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical group C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims description 3
- 229960001522 ximelagatran Drugs 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 206010013954 Dysphoria Diseases 0.000 claims description 2
- 208000036993 Frustration Diseases 0.000 claims description 2
- 206010022998 Irritability Diseases 0.000 claims description 2
- 206010057852 Nicotine dependence Diseases 0.000 claims description 2
- 108010028924 PPAR alpha Proteins 0.000 claims description 2
- 102000023984 PPAR alpha Human genes 0.000 claims description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 2
- 206010038743 Restlessness Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical group C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 2
- 201000006145 cocaine dependence Diseases 0.000 claims description 2
- 235000019788 craving Nutrition 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 206010013663 drug dependence Diseases 0.000 claims description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 2
- 206010021654 increased appetite Diseases 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 229940020573 plavix Drugs 0.000 claims description 2
- 229940051223 zetia Drugs 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- NMTKJEZOWHRAQY-UHFFFAOYSA-N 8-[(6-methoxyisoquinolin-4-yl)methyl]-1-methyl-3-(2-methylpropyl)-7h-purine-2,6-dione Chemical group CC(C)CN1C(=O)N(C)C(=O)C(N2)=C1N=C2CC1=CN=CC2=CC=C(OC)C=C21 NMTKJEZOWHRAQY-UHFFFAOYSA-N 0.000 claims 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 claims 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000005555 hypertensive agent Substances 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 abstract description 3
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 3
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 abstract 2
- 230000010085 airway hyperresponsiveness Effects 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000005586 smoking cessation Effects 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 description 64
- 229910052739 hydrogen Inorganic materials 0.000 description 56
- 239000001257 hydrogen Substances 0.000 description 56
- -1 aralkoxy Chemical group 0.000 description 37
- 230000003287 optical effect Effects 0.000 description 36
- 150000002431 hydrogen Chemical class 0.000 description 34
- 125000000217 alkyl group Chemical group 0.000 description 32
- 229910052736 halogen Inorganic materials 0.000 description 27
- 150000002367 halogens Chemical class 0.000 description 27
- 239000002253 acid Substances 0.000 description 25
- 229910052760 oxygen Inorganic materials 0.000 description 24
- 229910052717 sulfur Inorganic materials 0.000 description 23
- 239000000203 mixture Substances 0.000 description 21
- 125000003545 alkoxy group Chemical group 0.000 description 20
- 125000001072 heteroaryl group Chemical group 0.000 description 18
- 125000003118 aryl group Chemical group 0.000 description 17
- 125000003710 aryl alkyl group Chemical group 0.000 description 15
- 125000000547 substituted alkyl group Chemical group 0.000 description 15
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 125000004475 heteroaralkyl group Chemical group 0.000 description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 4
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 229960001722 verapamil Drugs 0.000 description 4
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 3
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 3
- 108010061435 Enalapril Proteins 0.000 description 3
- 108010063919 Glucagon Receptors Proteins 0.000 description 3
- 102100040890 Glucagon receptor Human genes 0.000 description 3
- 102000003729 Neprilysin Human genes 0.000 description 3
- 108090000028 Neprilysin Proteins 0.000 description 3
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 3
- 229960000528 amlodipine Drugs 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 3
- 229960000873 enalapril Drugs 0.000 description 3
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000003451 thiazide diuretic agent Substances 0.000 description 3
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 2
- MYHMSPXTUIKVGN-UHFFFAOYSA-N 1-[2-[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=C1)=CC=C1CC(=O)N1CCCC1C(O)=O MYHMSPXTUIKVGN-UHFFFAOYSA-N 0.000 description 2
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 2
- ZCTDTVUDURCGFX-UHFFFAOYSA-N 3-[(2-benzyl-3-sulfanylpropanoyl)amino]propanoic acid Chemical compound OC(=O)CCNC(=O)C(CS)CC1=CC=CC=C1 ZCTDTVUDURCGFX-UHFFFAOYSA-N 0.000 description 2
- ZPUTXMKXGFJLPJ-UHFFFAOYSA-N 3-[(2-naphthalen-2-yl-1,3-benzoxazol-5-yl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=C(C=CC2=CC=CC=C12)C=1OC2=C(N=1)C=C(C=C2)CN1C(SCC1=O)=O ZPUTXMKXGFJLPJ-UHFFFAOYSA-N 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
- MJHKIDXPBNVAGM-UHFFFAOYSA-N 5,6-bis(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(C=2N(C(=O)C=3C=NN(C=3N=2)C=2C=CC=CC=2)C=2C=C(C)C=CC=2)=C1 MJHKIDXPBNVAGM-UHFFFAOYSA-N 0.000 description 2
- BREBHAMOAQDITI-UHFFFAOYSA-N 5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(Cl)=CC=C1C(N(C1=O)C=2C=C(Cl)C=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 BREBHAMOAQDITI-UHFFFAOYSA-N 0.000 description 2
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
- 108010015181 PPAR delta Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960004530 benazepril Drugs 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 229960002490 fosinopril Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 2
- 229960001783 nicardipine Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 229960000715 nimodipine Drugs 0.000 description 2
- 229960000227 nisoldipine Drugs 0.000 description 2
- 229960005425 nitrendipine Drugs 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229960002582 perindopril Drugs 0.000 description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229960001455 quinapril Drugs 0.000 description 2
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 2
- 229960003401 ramipril Drugs 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- AXJRSRRSVKNLRF-JOCHJYFZSA-N (2r)-1-[2-[3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=1)=CC=CC=1CC(=O)N1CCC[C@@H]1C(O)=O AXJRSRRSVKNLRF-JOCHJYFZSA-N 0.000 description 1
- FBAOIPOOEGBIOR-HHHXNRCGSA-N (2r)-1-[2-[3-[[2-(4-cyanophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound N=1C(COC=2C=C(C=CC=2)C(C)(C)C(=O)N2C3=CC=CC=C3C[C@@H]2C(O)=O)=C(C)OC=1C1=CC=C(C#N)C=C1 FBAOIPOOEGBIOR-HHHXNRCGSA-N 0.000 description 1
- MCBDFKKRYBVIAV-JOCHJYFZSA-N (2r)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1COC(C=1)=CC=CC=1C(C)(C)C(=O)N1CCC[C@@H]1C(O)=O MCBDFKKRYBVIAV-JOCHJYFZSA-N 0.000 description 1
- NSQQCEJNBOAAGP-HXUWFJFHSA-N (2r)-1-[3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]sulfanylcarbonylpyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=1)=CC=CC=1SC(=O)N1CCC[C@@H]1C(O)=O NSQQCEJNBOAAGP-HXUWFJFHSA-N 0.000 description 1
- QIJLJZOGPPQCOG-NFAWXSAZSA-N (2s)-1-[(2s)-3-[(2r)-2-(cyclohexanecarbonylamino)propanoyl]sulfanyl-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound N([C@H](C)C(=O)SC[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)C1CCCCC1 QIJLJZOGPPQCOG-NFAWXSAZSA-N 0.000 description 1
- BLWKWOVOFWHFLD-FQEVSTJZSA-N (2s)-2-(2-benzoylanilino)-3-(4-hydroxyphenyl)propanoic acid Chemical class C([C@@H](C(=O)O)NC=1C(=CC=CC=1)C(=O)C=1C=CC=CC=1)C1=CC=C(O)C=C1 BLWKWOVOFWHFLD-FQEVSTJZSA-N 0.000 description 1
- KDQWIKMBLSWIPD-ABLWVSNPSA-N (2s)-2-[(2-benzyl-3-sulfanylpropanoyl)amino]-4,4-bis(methylsulfanyl)butanoic acid Chemical compound CSC(SC)C[C@@H](C(O)=O)NC(=O)C(CS)CC1=CC=CC=C1 KDQWIKMBLSWIPD-ABLWVSNPSA-N 0.000 description 1
- FGXXIAHRYGHABD-KGLIPLIRSA-N (2s)-2-[[(2s)-2-[(2-methylphenyl)methyl]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](CS)CC1=CC=CC=C1C FGXXIAHRYGHABD-KGLIPLIRSA-N 0.000 description 1
- PQSUQDFBGSIHKA-NEPJUHHUSA-N (2s)-2-hydroxy-3-[[(2s)-2-[(2-methylphenyl)methyl]-3-sulfanylpropanoyl]amino]propanoic acid Chemical compound CC1=CC=CC=C1C[C@H](CS)C(=O)NC[C@H](O)C(O)=O PQSUQDFBGSIHKA-NEPJUHHUSA-N 0.000 description 1
- UXOWGYHJODZGMF-IYQSZBERSA-N (2s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide Chemical compound COCCCOC1=CC(CC(CC(N)C(O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-IYQSZBERSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- MPULOWQWEXSORW-UHFFFAOYSA-N 1,6-diphenyl-5-(4-propan-2-ylphenyl)pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C(C)C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1 MPULOWQWEXSORW-UHFFFAOYSA-N 0.000 description 1
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 1
- OOMSUFVRQPKSIS-UHFFFAOYSA-N 1-[2-[3-[(4-methylphenyl)methoxy]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C1=CC(C)=CC=C1COC1=CC=CC(CC(=O)N2C(CCC2)C(O)=O)=C1 OOMSUFVRQPKSIS-UHFFFAOYSA-N 0.000 description 1
- GKSZYJFJGGPJEY-UHFFFAOYSA-N 1-[2-[3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=1)=CC=CC=1CC(=O)N1CCCC1C(O)=O GKSZYJFJGGPJEY-UHFFFAOYSA-N 0.000 description 1
- KVVODNUBDFULSC-UHFFFAOYSA-N 1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]phenyl]sulfonyl-2,3-dihydroindole-2-carboxylic acid Chemical compound N=1C(COC=2C=CC(=CC=2)S(=O)(=O)N2C3=CC=CC=C3CC2C(O)=O)=C(C)OC=1C1=CC=C(C(F)(F)F)C=C1 KVVODNUBDFULSC-UHFFFAOYSA-N 0.000 description 1
- TZESSPPAPLHFEQ-UHFFFAOYSA-N 2-[(2-benzyl-3-sulfanylpropanoyl)amino]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(NC(=O)C(CS)CC=2C=CC=CC=2)=N1 TZESSPPAPLHFEQ-UHFFFAOYSA-N 0.000 description 1
- XMQODGUTLZXUGZ-RPBOFIJWSA-N 2-[(3s)-3-[[1-[(2r)-2-ethoxycarbonyl-4-phenylbutyl]cyclopentanecarbonyl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic acid Chemical compound C([C@@H](C(=O)OCC)CC1(CCCC1)C(=O)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XMQODGUTLZXUGZ-RPBOFIJWSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 description 1
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 1
- SUKNXYMRQLQQMI-UHFFFAOYSA-N 3-[(2-benzyl-3-sulfanylpropanoyl)amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC(=O)C(CS)CC=2C=CC=CC=2)=C1 SUKNXYMRQLQQMI-UHFFFAOYSA-N 0.000 description 1
- UXTJLCWDHLUAQF-UHFFFAOYSA-N 3-[[2-(acetylsulfanylmethyl)-3-phenylpropanoyl]amino]benzoic acid Chemical compound C=1C=CC(C(O)=O)=CC=1NC(=O)C(CSC(=O)C)CC1=CC=CC=C1 UXTJLCWDHLUAQF-UHFFFAOYSA-N 0.000 description 1
- MZJKGGDSMYZXSC-UHFFFAOYSA-N 3-[[4-(2-indol-1-ylethoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1CC(C=C1)=CC=C1OCCN1C2=CC=CC=C2C=C1 MZJKGGDSMYZXSC-UHFFFAOYSA-N 0.000 description 1
- ZIGJSGLUSFDQKH-UHFFFAOYSA-N 3-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CN1C(=O)CSC1=O ZIGJSGLUSFDQKH-UHFFFAOYSA-N 0.000 description 1
- YZASIEYDSDLOPC-UHFFFAOYSA-N 3-[[4-[2-(2,3-dihydroindol-1-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N1(CCC2=CC=CC=C12)CCOC1=CC=C(C=C1)CN1C(SCC1=O)=O YZASIEYDSDLOPC-UHFFFAOYSA-N 0.000 description 1
- AQIIFRLJSGGKST-UHFFFAOYSA-N 3-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CN1C(=O)SCC1=O AQIIFRLJSGGKST-UHFFFAOYSA-N 0.000 description 1
- ZGRMKPSQTQQYNY-UHFFFAOYSA-N 3-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CN1C(=O)CSC1=O ZGRMKPSQTQQYNY-UHFFFAOYSA-N 0.000 description 1
- XJDLUGJGZAHMQE-UHFFFAOYSA-N 3-[[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CN1C(=O)CSC1=O XJDLUGJGZAHMQE-UHFFFAOYSA-N 0.000 description 1
- HMLWNNMYODLLJO-UHFFFAOYSA-N 3-methyl-1,3-thiazolidine-2,4-dione Chemical compound CN1C(=O)CSC1=O HMLWNNMYODLLJO-UHFFFAOYSA-N 0.000 description 1
- REPVVNYZORKKPQ-UHFFFAOYSA-N 3-oxo-3-[(1-phenyl-3-sulfanylpropan-2-yl)amino]propanoic acid Chemical compound OC(=O)CC(=O)NC(CS)CC1=CC=CC=C1 REPVVNYZORKKPQ-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- NCSNXXXLRVRXIM-UHFFFAOYSA-N 4-[(2-benzyl-3-sulfanylpropanoyl)amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC(=O)C(CS)CC1=CC=CC=C1 NCSNXXXLRVRXIM-UHFFFAOYSA-N 0.000 description 1
- VCFGVPMALWRCTK-UHFFFAOYSA-N 4-[(2-benzyl-3-sulfanylpropanoyl)amino]thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC(NC(=O)C(CS)CC=2C=CC=CC=2)=C1 VCFGVPMALWRCTK-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- HLYRSBSWPJDADE-UHFFFAOYSA-N 5,6-bis(2-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC=C1C(N(C1=O)C=2C(=CC=CC=2)C)=NC2=C1C=NN2C1=CC=CC=C1 HLYRSBSWPJDADE-UHFFFAOYSA-N 0.000 description 1
- GDHPGXMZIAFXCN-UHFFFAOYSA-N 5,6-bis(4-bromophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(Br)=CC=C1C(N(C1=O)C=2C=CC(Br)=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 GDHPGXMZIAFXCN-UHFFFAOYSA-N 0.000 description 1
- VXDBYEDOONMQMV-UHFFFAOYSA-N 5,6-bis(4-chlorophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(Cl)=CC=C1C(N(C1=O)C=2C=CC(Cl)=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 VXDBYEDOONMQMV-UHFFFAOYSA-N 0.000 description 1
- IIQWUHIWAXFABY-UHFFFAOYSA-N 5,6-bis(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1C(N(C1=O)C=2C=CC(C)=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 IIQWUHIWAXFABY-UHFFFAOYSA-N 0.000 description 1
- BUSHPLPJLFMRIS-UHFFFAOYSA-N 5-(2-methylphenyl)-1,6-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1 BUSHPLPJLFMRIS-UHFFFAOYSA-N 0.000 description 1
- QDMNYILTVWAKSY-UHFFFAOYSA-N 5-(2-methylphenyl)-6-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1C(N(C1=O)C=2C(=CC=CC=2)C)=NC2=C1C=NN2C1=CC=CC=C1 QDMNYILTVWAKSY-UHFFFAOYSA-N 0.000 description 1
- GJTYAKKSVFSNAE-UHFFFAOYSA-N 5-(3,5-dimethylphenyl)-6-(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(C=2N(C(=O)C=3C=NN(C=3N=2)C=2C=CC=CC=2)C=2C=C(C)C=C(C)C=2)=C1 GJTYAKKSVFSNAE-UHFFFAOYSA-N 0.000 description 1
- WPYGRQTXWXUSEV-UHFFFAOYSA-N 5-(3-chlorophenyl)-1,6-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound ClC1=CC=CC(N2C(C=3C=NN(C=3N=C2C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 WPYGRQTXWXUSEV-UHFFFAOYSA-N 0.000 description 1
- CWRJPIDSWJRJIT-UHFFFAOYSA-N 5-(3-chlorophenyl)-6-(2-fluorophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound FC1=CC=CC=C1C(N(C1=O)C=2C=C(Cl)C=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 CWRJPIDSWJRJIT-UHFFFAOYSA-N 0.000 description 1
- AROPKPIERSUSNA-UHFFFAOYSA-N 5-(3-chlorophenyl)-6-(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(C=2N(C(=O)C=3C=NN(C=3N=2)C=2C=CC=CC=2)C=2C=C(Cl)C=CC=2)=C1 AROPKPIERSUSNA-UHFFFAOYSA-N 0.000 description 1
- PFIRLQMLQPBDIH-UHFFFAOYSA-N 5-(3-chlorophenyl)-6-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1C(N(C1=O)C=2C=C(Cl)C=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 PFIRLQMLQPBDIH-UHFFFAOYSA-N 0.000 description 1
- YWXLLWNVTQDKIP-UHFFFAOYSA-N 5-(3-methylphenyl)-1,6-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(N2C(C=3C=NN(C=3N=C2C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 YWXLLWNVTQDKIP-UHFFFAOYSA-N 0.000 description 1
- SALFRPOHLBLOIS-UHFFFAOYSA-N 5-(3-methylphenyl)-6-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1C(N(C1=O)C=2C=C(C)C=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 SALFRPOHLBLOIS-UHFFFAOYSA-N 0.000 description 1
- JMEWNABJMKGPPW-UHFFFAOYSA-N 5-(4-bromophenyl)-1,6-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(Br)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1 JMEWNABJMKGPPW-UHFFFAOYSA-N 0.000 description 1
- KCSXPQZNRWZJTJ-UHFFFAOYSA-N 5-(4-bromophenyl)-6-(4-chlorophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(Cl)=CC=C1C(N(C1=O)C=2C=CC(Br)=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 KCSXPQZNRWZJTJ-UHFFFAOYSA-N 0.000 description 1
- VRXFDXJDRFCQEU-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(C=2N(C(=O)C=3C=NN(C=3N=2)C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 VRXFDXJDRFCQEU-UHFFFAOYSA-N 0.000 description 1
- RLLFOGZEYMBDAC-UHFFFAOYSA-N 5-(4-ethoxyphenyl)-1,6-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OCC)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1 RLLFOGZEYMBDAC-UHFFFAOYSA-N 0.000 description 1
- OBKCCUHDEJMTCI-UHFFFAOYSA-N 5-(4-ethoxyphenyl)-6-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OCC)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(C)C=C1 OBKCCUHDEJMTCI-UHFFFAOYSA-N 0.000 description 1
- HQBCTHNFYGFTAV-UHFFFAOYSA-N 5-(4-fluorophenyl)-6-(2-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC=C1C(N(C1=O)C=2C=CC(F)=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 HQBCTHNFYGFTAV-UHFFFAOYSA-N 0.000 description 1
- ALCGTUDMLRZXKN-UHFFFAOYSA-N 5-(4-fluorophenyl)-6-(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(C=2N(C(=O)C=3C=NN(C=3N=2)C=2C=CC=CC=2)C=2C=CC(F)=CC=2)=C1 ALCGTUDMLRZXKN-UHFFFAOYSA-N 0.000 description 1
- FBCKUZYUFVWIBZ-UHFFFAOYSA-N 5-(4-fluorophenyl)-6-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1C(N(C1=O)C=2C=CC(F)=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 FBCKUZYUFVWIBZ-UHFFFAOYSA-N 0.000 description 1
- ZSQUVPGLHAWOPI-UHFFFAOYSA-N 5-(4-methoxyphenyl)-1,6-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1 ZSQUVPGLHAWOPI-UHFFFAOYSA-N 0.000 description 1
- XGJYMGFLZJCJHO-UHFFFAOYSA-N 5-(4-methoxyphenyl)-6-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(C)C=C1 XGJYMGFLZJCJHO-UHFFFAOYSA-N 0.000 description 1
- WGPDUTXOBVXSRI-UHFFFAOYSA-N 5-(4-methylphenyl)-1,6-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1 WGPDUTXOBVXSRI-UHFFFAOYSA-N 0.000 description 1
- AUTCHGUUOVSZOZ-UHFFFAOYSA-N 5-[(4-methylphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1CC1C(=O)NC(=O)S1 AUTCHGUUOVSZOZ-UHFFFAOYSA-N 0.000 description 1
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- JEZSDRHESDMHBO-UHFFFAOYSA-N 6-(2-fluorophenyl)-1,5-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound FC1=CC=CC=C1C(N(C1=O)C=2C=CC=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 JEZSDRHESDMHBO-UHFFFAOYSA-N 0.000 description 1
- IODYPLNWORELCU-UHFFFAOYSA-N 6-(2-fluorophenyl)-1-phenyl-5-(4-propan-2-ylphenyl)pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C(C)C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1F IODYPLNWORELCU-UHFFFAOYSA-N 0.000 description 1
- BUKRCICRNQXJCV-UHFFFAOYSA-N 6-(2-fluorophenyl)-5-(2-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1F BUKRCICRNQXJCV-UHFFFAOYSA-N 0.000 description 1
- JGNDNQVVNPAJMT-UHFFFAOYSA-N 6-(2-fluorophenyl)-5-(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(N2C(C=3C=NN(C=3N=C2C=2C(=CC=CC=2)F)C=2C=CC=CC=2)=O)=C1 JGNDNQVVNPAJMT-UHFFFAOYSA-N 0.000 description 1
- ABDXHFUCCHDUCQ-UHFFFAOYSA-N 6-(2-methylphenyl)-5-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1C ABDXHFUCCHDUCQ-UHFFFAOYSA-N 0.000 description 1
- SIOYQFGOQWFIAP-UHFFFAOYSA-N 6-(3-methylphenyl)-1-phenyl-5-(4-propan-2-ylphenyl)pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C(C)C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC(C)=C1 SIOYQFGOQWFIAP-UHFFFAOYSA-N 0.000 description 1
- BREWTGIDLCMGIM-UHFFFAOYSA-N 6-(3-methylphenyl)-1-phenyl-5H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1(=CC=CC=C1)N1N=CC2=C1N=C(NC2=O)C=1C=C(C=CC=1)C BREWTGIDLCMGIM-UHFFFAOYSA-N 0.000 description 1
- ICPPYPLLKATGNJ-UHFFFAOYSA-N 6-(4-bromophenyl)-5-(2,4-dimethylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC(C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(Br)C=C1 ICPPYPLLKATGNJ-UHFFFAOYSA-N 0.000 description 1
- KHTGFAORQYAINE-UHFFFAOYSA-N 6-(4-bromophenyl)-5-(3-chlorophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound ClC1=CC=CC(N2C(C=3C=NN(C=3N=C2C=2C=CC(Br)=CC=2)C=2C=CC=CC=2)=O)=C1 KHTGFAORQYAINE-UHFFFAOYSA-N 0.000 description 1
- PQUAVOZDTLFRAH-UHFFFAOYSA-N 6-(4-bromophenyl)-5-(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(N2C(C=3C=NN(C=3N=C2C=2C=CC(Br)=CC=2)C=2C=CC=CC=2)=O)=C1 PQUAVOZDTLFRAH-UHFFFAOYSA-N 0.000 description 1
- AGQPWOSMZZJEJK-UHFFFAOYSA-N 6-(4-bromophenyl)-5-(4-ethoxyphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OCC)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(Br)C=C1 AGQPWOSMZZJEJK-UHFFFAOYSA-N 0.000 description 1
- WPQHRZBAWPIZPT-UHFFFAOYSA-N 6-(4-bromophenyl)-5-(4-fluorophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(Br)C=C1 WPQHRZBAWPIZPT-UHFFFAOYSA-N 0.000 description 1
- NVLXAGRSNYTNGV-UHFFFAOYSA-N 6-(4-chlorophenyl)-5-(2-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(Cl)C=C1 NVLXAGRSNYTNGV-UHFFFAOYSA-N 0.000 description 1
- FCEIPDQFWTUOGR-UHFFFAOYSA-N 6-(4-chlorophenyl)-5-(3,5-dimethylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC(C)=CC(N2C(C=3C=NN(C=3N=C2C=2C=CC(Cl)=CC=2)C=2C=CC=CC=2)=O)=C1 FCEIPDQFWTUOGR-UHFFFAOYSA-N 0.000 description 1
- BYDDPXHDRAOTMO-UHFFFAOYSA-N 6-(4-chlorophenyl)-5-(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(N2C(C=3C=NN(C=3N=C2C=2C=CC(Cl)=CC=2)C=2C=CC=CC=2)=O)=C1 BYDDPXHDRAOTMO-UHFFFAOYSA-N 0.000 description 1
- XCDRNJXUUVWVMT-UHFFFAOYSA-N 6-(4-chlorophenyl)-5-(4-ethoxyphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OCC)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(Cl)C=C1 XCDRNJXUUVWVMT-UHFFFAOYSA-N 0.000 description 1
- ODXXXUPCSZTRQJ-UHFFFAOYSA-N 6-(4-chlorophenyl)-5-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(Cl)C=C1 ODXXXUPCSZTRQJ-UHFFFAOYSA-N 0.000 description 1
- POYSPKBDRLZYEA-UHFFFAOYSA-N 6-(4-methylphenyl)-1,5-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1C(N(C1=O)C=2C=CC=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 POYSPKBDRLZYEA-UHFFFAOYSA-N 0.000 description 1
- KJVKOEVEFLXJES-UHFFFAOYSA-N 7-[(2-benzyl-3-sulfanylpropanoyl)amino]heptanoic acid Chemical compound OC(=O)CCCCCCNC(=O)C(CS)CC1=CC=CC=C1 KJVKOEVEFLXJES-UHFFFAOYSA-N 0.000 description 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- RABHRUHISCNGPW-UHFFFAOYSA-N CC1=C(N=C(O1)C1=CC=CC=C1)C(COC1=CC=C(CN2C(SCC2=O)=O)C=C1)O Chemical compound CC1=C(N=C(O1)C1=CC=CC=C1)C(COC1=CC=C(CN2C(SCC2=O)=O)C=C1)O RABHRUHISCNGPW-UHFFFAOYSA-N 0.000 description 1
- 101150062316 CHRNA2 gene Proteins 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 108010064945 D-4F peptide Proteins 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 108010018112 LY 315902 Proteins 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
- 206010042957 Systolic hypertension Diseases 0.000 description 1
- 108010036928 Thiorphan Proteins 0.000 description 1
- ZROUQTNYPCANTN-UHFFFAOYSA-N Tiapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC1(C=2C=C(OC)C(OC)=CC=2)S(=O)(=O)CCCS1(=O)=O ZROUQTNYPCANTN-UHFFFAOYSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 241000927721 Tritia Species 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 229950007884 alacepril Drugs 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- KLRSDBSKUSSCGU-KRQUFFFQSA-N aliskiren fumarate Chemical compound OC(=O)\C=C\C(O)=O.COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC.COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC KLRSDBSKUSSCGU-KRQUFFFQSA-N 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- PHFDAOXXIZOUIX-UHFFFAOYSA-N anipamil Chemical compound C=1C=CC(OC)=CC=1C(CCCCCCCCCCCC)(C#N)CCCN(C)CCC1=CC=CC(OC)=C1 PHFDAOXXIZOUIX-UHFFFAOYSA-N 0.000 description 1
- 229950011530 anipamil Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- ZTWZVMIYIIVABD-OEMFJLHTSA-N candoxatril Chemical compound C([C@@H](COCCOC)C(=O)OC=1C=C2CCCC2=CC=1)C1(C(=O)N[C@@H]2CC[C@@H](CC2)C(O)=O)CCCC1 ZTWZVMIYIIVABD-OEMFJLHTSA-N 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 229950005749 ceronapril Drugs 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 1
- 229950006689 darglitazone Drugs 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 229950002375 englitazone Drugs 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZVQXPUMRSJGLSF-ZVAWYAOSSA-N ethyl (2s)-2-[[2-(acetylsulfanylmethyl)-3-(2-methylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)C(CSC(C)=O)CC1=CC=CC=C1C ZVQXPUMRSJGLSF-ZVAWYAOSSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960002602 fendiline Drugs 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 229960001195 imidapril Drugs 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940045623 meridia Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229950006549 moveltipril Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- VZWXXKDFACOXNT-UHFFFAOYSA-N niludipine Chemical compound CCCOCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCOCCC)C1C1=CC=CC([N+]([O-])=O)=C1 VZWXXKDFACOXNT-UHFFFAOYSA-N 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229940126347 non-steroidal aldosterone synthase inhibitor Drugs 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 1
- 108010072906 phosphoramidon Proteins 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229960001989 prenylamine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108700016891 retrothiorphan Proteins 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960002909 spirapril Drugs 0.000 description 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
- 108700035424 spirapril Proteins 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229960004084 temocapril Drugs 0.000 description 1
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 description 1
- 229950003137 tiapamil Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60831004P | 2004-09-09 | 2004-09-09 | |
| US60957704P | 2004-09-14 | 2004-09-14 | |
| US68973805P | 2005-06-10 | 2005-06-10 | |
| PCT/US2005/032224 WO2006029349A1 (en) | 2004-09-09 | 2005-09-08 | Combination of organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007002879A true MX2007002879A (es) | 2007-04-23 |
Family
ID=35385557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007002879A MX2007002879A (es) | 2004-09-09 | 2005-09-08 | Combinacion de compuestos organicos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070299047A1 (enExample) |
| EP (1) | EP1791600A1 (enExample) |
| JP (1) | JP2008512486A (enExample) |
| KR (1) | KR20070106677A (enExample) |
| AR (1) | AR050631A1 (enExample) |
| AU (1) | AU2005282290B2 (enExample) |
| BR (1) | BRPI0515185A (enExample) |
| CA (1) | CA2578290A1 (enExample) |
| GT (1) | GT200500246A (enExample) |
| MX (1) | MX2007002879A (enExample) |
| PE (1) | PE20060594A1 (enExample) |
| TW (1) | TW200621220A (enExample) |
| WO (1) | WO2006029349A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| ES2708552T3 (es) | 2002-12-20 | 2019-04-10 | Niconovum Ab | Método para la preparación de un material particulado que contiene nicotina con una celulosa cristalina (en particular MCC) |
| WO2007104573A2 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
| EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US20160331729A9 (en) * | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| AU2013201889A1 (en) * | 2007-04-11 | 2013-04-11 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| MX2009010854A (es) | 2007-04-11 | 2010-01-28 | Omeros Corp | Composiciones y metodos para profilaxis y tratamiento de adicciones. |
| IE20070928A1 (en) * | 2007-12-21 | 2009-09-30 | Giuliani Int Ltd | Multi target ligands |
| WO2009154230A1 (ja) * | 2008-06-17 | 2009-12-23 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| PT2396081T (pt) | 2009-02-16 | 2017-07-11 | Nogra Pharma Ltd | Compostos alquilamido e suas utilizações |
| KR101767273B1 (ko) | 2009-03-11 | 2017-08-10 | 오메로스 코포레이션 | 중독의 예방 및 치료용 조성물 및 방법 |
| WO2011100659A2 (en) * | 2010-02-12 | 2011-08-18 | Kitov Pharmaceutical Ltd. | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
| EP2663304B1 (en) | 2011-01-11 | 2019-11-20 | Dimerix Bioscience Pty Ltd | Combination therapy |
| WO2013071077A1 (en) | 2011-11-09 | 2013-05-16 | Cornell University | The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies |
| EP2811993B1 (en) | 2012-02-09 | 2019-10-09 | Nogra Pharma Limited | Methods of treating fibrosis |
| US20220142985A1 (en) * | 2018-08-10 | 2022-05-12 | Servicio Andaluz De Salud | Agents for treatment of alcohol use disorder |
| SI3921299T1 (sl) | 2019-02-08 | 2025-03-31 | Nogra Pharma Limited | Postopek izdelave 3-(4'-aminofenil)-2-metoksipropionske kisline in njenih analogov in vmesnih proizvodov |
| CA3204074A1 (en) | 2020-12-03 | 2022-06-09 | Delta 4 Gmbh | Clopidogrel for use in the treatment of focal segmental glomerulosclerosis (fsgs) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3800038A (en) * | 1972-04-21 | 1974-03-26 | Biolog Concepts Inc | Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier |
| FR2530247B1 (fr) * | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| TWI238827B (en) * | 1995-12-21 | 2005-09-01 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
| US6488961B1 (en) * | 1996-09-20 | 2002-12-03 | Ethypharm, Inc. | Effervescent granules and methods for their preparation |
| US6071539A (en) * | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
| US7019010B2 (en) * | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| TW200303742A (en) * | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| US7652061B2 (en) * | 2003-05-20 | 2010-01-26 | Novartis A.G. | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors |
-
2005
- 2005-09-07 AR ARP050103737A patent/AR050631A1/es unknown
- 2005-09-07 GT GT200500246A patent/GT200500246A/es unknown
- 2005-09-07 PE PE2005001034A patent/PE20060594A1/es not_active Application Discontinuation
- 2005-09-08 BR BRPI0515185-6A patent/BRPI0515185A/pt not_active IP Right Cessation
- 2005-09-08 KR KR1020077007858A patent/KR20070106677A/ko not_active Withdrawn
- 2005-09-08 TW TW094130818A patent/TW200621220A/zh unknown
- 2005-09-08 WO PCT/US2005/032224 patent/WO2006029349A1/en not_active Ceased
- 2005-09-08 MX MX2007002879A patent/MX2007002879A/es not_active Application Discontinuation
- 2005-09-08 AU AU2005282290A patent/AU2005282290B2/en not_active Expired - Fee Related
- 2005-09-08 US US11/574,994 patent/US20070299047A1/en not_active Abandoned
- 2005-09-08 EP EP05796483A patent/EP1791600A1/en not_active Withdrawn
- 2005-09-08 JP JP2007531384A patent/JP2008512486A/ja not_active Withdrawn
- 2005-09-08 CA CA002578290A patent/CA2578290A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070106677A (ko) | 2007-11-05 |
| WO2006029349A1 (en) | 2006-03-16 |
| BRPI0515185A (pt) | 2008-07-22 |
| AU2005282290B2 (en) | 2009-06-25 |
| JP2008512486A (ja) | 2008-04-24 |
| GT200500246A (es) | 2006-04-17 |
| PE20060594A1 (es) | 2006-08-18 |
| US20070299047A1 (en) | 2007-12-27 |
| CA2578290A1 (en) | 2006-03-16 |
| TW200621220A (en) | 2006-07-01 |
| EP1791600A1 (en) | 2007-06-06 |
| AR050631A1 (es) | 2006-11-08 |
| AU2005282290A1 (en) | 2006-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005282290B2 (en) | Combination of organic compounds | |
| US7019010B2 (en) | Combinations | |
| CN101374523B (zh) | 用于治疗糖尿病的二肽基肽酶抑制剂 | |
| EP1432423A2 (en) | Pharmaceutical combinations of pde-v inhibitors and other agents | |
| KR20070099527A (ko) | 유기 화합물의 조합물 | |
| KR20150032590A (ko) | 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도 | |
| CN101778633A (zh) | 二肽基肽酶抑制剂的每周给药 | |
| EP1248604A2 (en) | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents | |
| AU2007264002B2 (en) | Use of PKC inhibitors in diabetic complications | |
| KR20090075747A (ko) | 부종의 발병을 예방, 지연 또는 감소시키기 위한 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |